Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Ovarian Neoplasms 2Lung Neoplasms 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Neuroendocrine Tumors 1Fallopian Tube Neoplasms 1Carcinoma, Small Cell 1

Interventions

Cisplatin 4Pemetrexed 3Etoposide 3Topotecan 2Gemcitabine 2Carboplatin 2vosaroxin 1vinflunine 1veliparib 1taxane 1pomalidomide 1pembrolizumab 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1apalutamide 1abiraterone 1Vinorelbine 1Tomography, X-Ray Computed 1Temozolomide 1Radiation 1RRx-001 1Positron-Emission Tomography 1Podophyllotoxin 1Platinum 1Paclitaxel 1Irinotecan 1Histamine Antagonists 1GSK2879552 1Epinephrine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Small Cell × taxane × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡